CL2017002854A1 - Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamin - Google Patents
Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketaminInfo
- Publication number
- CL2017002854A1 CL2017002854A1 CL2017002854A CL2017002854A CL2017002854A1 CL 2017002854 A1 CL2017002854 A1 CL 2017002854A1 CL 2017002854 A CL2017002854 A CL 2017002854A CL 2017002854 A CL2017002854 A CL 2017002854A CL 2017002854 A1 CL2017002854 A1 CL 2017002854A1
- Authority
- CL
- Chile
- Prior art keywords
- salt
- ketamine
- processes
- preparation
- ketamin
- Prior art date
Links
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical class C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 title abstract 5
- 150000003839 salts Chemical class 0.000 title abstract 2
- 229960003299 ketamine Drugs 0.000 abstract 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 abstract 1
- 229960000450 esketamine Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000004682 monohydrates Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/23—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/19—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
<p>La presente invención está dirigida a procesos para la preparación de esketamina. La presente invención está dirigida, además, a procesos para la resolución de S-ketamina a partir de una mezcla racémica o enantioméricamente enriquecida de ketamina. La presente invención está dirigida, además, a una sal de (S)-CSA de S-ketamina, más particularmente, una forma monohidrato de la sal de (S)-CSA de S-ketamina; y a una sal de (R)-CSA de R-ketamina.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562160659P | 2015-05-13 | 2015-05-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017002854A1 true CL2017002854A1 (es) | 2018-04-20 |
Family
ID=56068863
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017002854A CL2017002854A1 (es) | 2015-05-13 | 2017-11-10 | Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamin |
| CL2019001066A CL2019001066A1 (es) | 2015-05-13 | 2019-04-18 | Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina (divisional solicitud 201702854) |
| CL2020001852A CL2020001852A1 (es) | 2015-05-13 | 2020-07-13 | Procesos de preparación de s-ketamina o clorhidrato de s-ketamina o productos derivados de éste. (divisional solicitud 201901066) |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019001066A CL2019001066A1 (es) | 2015-05-13 | 2019-04-18 | Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina (divisional solicitud 201702854) |
| CL2020001852A CL2020001852A1 (es) | 2015-05-13 | 2020-07-13 | Procesos de preparación de s-ketamina o clorhidrato de s-ketamina o productos derivados de éste. (divisional solicitud 201901066) |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US20160332962A1 (es) |
| EP (1) | EP3294704B1 (es) |
| JP (1) | JP6882990B2 (es) |
| KR (1) | KR102610047B1 (es) |
| CN (1) | CN107750245B (es) |
| AU (1) | AU2016260911B2 (es) |
| BR (1) | BR112017024243B1 (es) |
| CA (1) | CA2985696A1 (es) |
| CL (3) | CL2017002854A1 (es) |
| CO (1) | CO2017011553A2 (es) |
| CR (1) | CR20170517A (es) |
| EA (1) | EA201792503A1 (es) |
| EC (1) | ECSP17075386A (es) |
| ES (1) | ES2767708T3 (es) |
| GT (1) | GT201700245A (es) |
| HK (1) | HK1251546A1 (es) |
| IL (1) | IL255433B2 (es) |
| MX (1) | MX2017014473A (es) |
| MY (1) | MY181938A (es) |
| PE (1) | PE20180527A1 (es) |
| PH (1) | PH12017502024A1 (es) |
| SA (1) | SA517390322B1 (es) |
| UA (1) | UA121049C2 (es) |
| WO (1) | WO2016180984A1 (es) |
| ZA (1) | ZA201708417B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105073096A (zh) | 2013-03-15 | 2015-11-18 | 詹森药业有限公司 | S-盐酸氯胺酮的药物组合物 |
| MX2017001908A (es) | 2014-08-13 | 2017-08-08 | Janssen Pharmaceutica Nv | Metodo para el tratamiento de la depresion. |
| MX2017003366A (es) | 2014-09-15 | 2018-02-01 | Janssen Pharmaceutica Nv | Regimenes de dosificacion y métodos especificos para el tratamiento de la depresión con el genotipo val66met (snp rs6265). |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| RU2020123893A (ru) | 2017-12-22 | 2022-01-24 | Янссен Фармасьютикалз, Инк. | Эскетамин для лечения депрессии |
| DK3505157T3 (da) * | 2017-12-29 | 2022-02-28 | Celon Pharma Sa | Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression |
| US11980595B2 (en) | 2018-02-15 | 2024-05-14 | National University Corporation Chiba University | Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases |
| CN110218157B (zh) * | 2018-03-01 | 2022-08-23 | 江苏恒瑞医药股份有限公司 | 一种r-氯胺酮及其可药用盐的制备方法 |
| CA3099293A1 (en) | 2018-05-04 | 2019-11-07 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| EP3813807A1 (en) * | 2018-06-27 | 2021-05-05 | Clexio Biosciences Ltd. | Method of treating major depressive disorder |
| CN108659004B (zh) * | 2018-07-12 | 2020-11-10 | 福安药业集团重庆博圣制药有限公司 | 奥拉西坦异构体的制备方法 |
| CN112702995A (zh) | 2018-10-05 | 2021-04-23 | 克雷西奥生物科技有限公司 | 治疗重度抑郁症的艾氯胺酮的治疗方案 |
| MA55218A (fr) | 2019-03-05 | 2022-01-12 | Janssen Pharmaceuticals Inc | Eskétamine pour le traitement de la dépression |
| US20220220062A1 (en) * | 2019-04-16 | 2022-07-14 | Janssen Pharmaceutica Nv | Synthetic methods of preparing esketamine |
| CN112375005A (zh) * | 2019-08-16 | 2021-02-19 | 国药集团工业有限公司 | 一种氯胺酮、其衍生物或其盐的消旋化方法 |
| WO2022208144A1 (en) * | 2021-03-31 | 2022-10-06 | Supriya Lifescience Ltd | A crystalline form of 2-(2-chlorophenyl)-2-(methylamino) cyclohexanone hydrochloride and method thereof |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH535201A (de) * | 1969-12-19 | 1973-03-31 | Bristol Myers Co | Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren |
| JPS5857420B2 (ja) * | 1975-02-12 | 1983-12-20 | ワコウジユンヤクコウギヨウ カブシキガイシヤ | Ｄｌ− フエニルグリシンノ コウガクブンカツホウホウ |
| JPS632932A (ja) | 1986-06-23 | 1988-01-07 | Teijin Ltd | 経鼻投与用粉末状組成物 |
| JPS6314771A (ja) * | 1986-07-08 | 1988-01-21 | Sankyo Co Ltd | 光学活性イミダゾ−ル誘導体およびその製法 |
| JPS63192753A (ja) * | 1987-02-05 | 1988-08-10 | Otsuka Pharmaceut Co Ltd | テトラヒドロキノリン誘導体の光学分割法 |
| DE4312016A1 (de) | 1993-04-13 | 1994-10-20 | Goedecke Ag | Stabile Ketamin-Lösungen |
| US5543434A (en) | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
| AU3842795A (en) | 1994-10-17 | 1996-05-06 | Akzo Nobel N.V. | Process for separating enantiomers from a racemic mixture |
| PE8798A1 (es) | 1995-07-17 | 1998-03-02 | Pfizer | Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil] |
| DE19619665C2 (de) * | 1996-05-15 | 2001-03-08 | Goedecke Ag | Racemattrennung von Ketamin |
| TW430660B (en) * | 1996-05-30 | 2001-04-21 | Mochida Pharm Co Ltd | Novel benzindole derivatives for neuron cell protection, processes for production, and the pharmaceutical compounds containing them |
| CN1205922C (zh) | 1998-07-24 | 2005-06-15 | 柳署弘 | 制备含有胆汁酸的澄清水溶液剂型 |
| US6176242B1 (en) | 1999-04-30 | 2001-01-23 | Medtronic Inc | Method of treating manic depression by brain infusion |
| EP1103256A1 (de) | 1999-11-26 | 2001-05-30 | Claudius Dr. med. Böck | Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom |
| BRPI0002693B8 (pt) * | 2000-06-19 | 2021-05-25 | Cristalia Produtos Quim Farmaceuticos Ltda | processo de obtenção dos enantiômeros da cetamina e seus sais farmaceuticamente aceitáveis |
| EP1551393A4 (en) | 2002-07-30 | 2010-06-16 | Peter Migaly | COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS |
| US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| US7687080B2 (en) | 2002-11-25 | 2010-03-30 | Taraxos Inc. | Treatment of neuropathy |
| US20040214215A1 (en) | 2003-03-07 | 2004-10-28 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
| US20060276550A1 (en) | 2005-06-03 | 2006-12-07 | Dileep Bhagwat | Topical compositions of ketamine and butamben and methods of their use |
| US8785500B2 (en) | 2006-03-22 | 2014-07-22 | Icahn School Of Medicine At Mount Sinai | Intranasal administration of ketamine to treat depression |
| ES2331162T3 (es) * | 2006-04-21 | 2009-12-22 | Zach System S.P.A. | Proceso para la preparacion de dorzolamida. |
| EP2029136A4 (en) | 2006-05-22 | 2010-01-06 | Vanda Pharmaceuticals Inc | TREATMENT FOR DEPRESSION DISEASES |
| DE102007009888A1 (de) | 2007-02-28 | 2008-09-04 | Hermann, Holger Lars, Dr. | Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen |
| WO2009131794A1 (en) * | 2008-03-27 | 2009-10-29 | University Of Kentucky Research Foundation | Opioid-ketamine and norketamine codrug combinations for pain management |
| US20110038807A1 (en) | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
| US20120225949A1 (en) | 2009-08-14 | 2012-09-06 | Demitri Papalos | Compositions and methods for treating bipolar disorder |
| EP2582366B1 (en) | 2010-06-15 | 2015-10-28 | Grünenthal GmbH | Pharmaceutical combination for the treatment of pain |
| US9012486B2 (en) * | 2011-11-14 | 2015-04-21 | Alex Chervinsky | Topical composition for pain relief |
| MX354547B (es) | 2011-11-14 | 2018-03-09 | Alfasigma Spa | Ensayos y métodos para seleccionar un regimen de tratamiento para un sujeto con depresión. |
| CN104519878A (zh) | 2012-03-12 | 2015-04-15 | 詹森药业有限公司 | 用于治疗顽固性或难治性抑郁症的艾氯胺酮 |
| AU2013305580A1 (en) | 2012-08-23 | 2015-04-09 | Stuart L. Weg | Anxiolytic composition, formulation and method of use |
| US20150259277A1 (en) | 2012-10-08 | 2015-09-17 | James Wallace Sleigh | Ketamine Derivatives |
| PL2968221T3 (pl) | 2013-03-15 | 2020-01-31 | Janssen Pharmaceutica Nv | Kompozycja farmaceutyczna chlorowodorku S-ketaminy |
| CN105073096A (zh) | 2013-03-15 | 2015-11-18 | 詹森药业有限公司 | S-盐酸氯胺酮的药物组合物 |
| CN112057441A (zh) | 2013-04-12 | 2020-12-11 | 西奈山伊坎医学院 | 创伤后应激障碍的治疗方法 |
| LT3043785T (lt) * | 2013-09-13 | 2021-12-10 | National University Corporation Chiba University | R-ketamino ir jo druskų vartojimas kaip vaistų |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| US20160338977A1 (en) | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
-
2016
- 2016-05-12 US US15/152,705 patent/US20160332962A1/en not_active Abandoned
- 2016-05-13 UA UAA201712292A patent/UA121049C2/uk unknown
- 2016-05-13 CA CA2985696A patent/CA2985696A1/en active Pending
- 2016-05-13 PE PE2017002412A patent/PE20180527A1/es unknown
- 2016-05-13 CR CR20170517A patent/CR20170517A/es unknown
- 2016-05-13 BR BR112017024243-5A patent/BR112017024243B1/pt active IP Right Grant
- 2016-05-13 MY MYPI2017704244A patent/MY181938A/en unknown
- 2016-05-13 EP EP16724354.2A patent/EP3294704B1/en active Active
- 2016-05-13 JP JP2017558956A patent/JP6882990B2/ja active Active
- 2016-05-13 ES ES16724354T patent/ES2767708T3/es active Active
- 2016-05-13 EA EA201792503A patent/EA201792503A1/ru unknown
- 2016-05-13 CN CN201680027740.1A patent/CN107750245B/zh active Active
- 2016-05-13 MX MX2017014473A patent/MX2017014473A/es active IP Right Grant
- 2016-05-13 WO PCT/EP2016/060922 patent/WO2016180984A1/en active Application Filing
- 2016-05-13 AU AU2016260911A patent/AU2016260911B2/en active Active
- 2016-05-13 KR KR1020177035694A patent/KR102610047B1/ko active IP Right Grant
-
2017
- 2017-11-05 IL IL255433A patent/IL255433B2/en unknown
- 2017-11-07 PH PH12017502024A patent/PH12017502024A1/en unknown
- 2017-11-10 CL CL2017002854A patent/CL2017002854A1/es unknown
- 2017-11-10 CO CONC2017/0011553A patent/CO2017011553A2/es unknown
- 2017-11-12 SA SA517390322A patent/SA517390322B1/ar unknown
- 2017-11-13 EC ECIEPI201775386A patent/ECSP17075386A/es unknown
- 2017-11-13 GT GT201700245A patent/GT201700245A/es unknown
- 2017-12-12 ZA ZA2017/08417A patent/ZA201708417B/en unknown
-
2018
- 2018-06-04 US US15/997,267 patent/US10815196B2/en active Active
- 2018-08-31 HK HK18111186.1A patent/HK1251546A1/zh unknown
-
2019
- 2019-04-18 CL CL2019001066A patent/CL2019001066A1/es unknown
-
2020
- 2020-07-13 CL CL2020001852A patent/CL2020001852A1/es unknown
- 2020-10-08 US US17/066,127 patent/US20210024461A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017002854A1 (es) | Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamin | |
| EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
| EA201890899A1 (ru) | Модуляторы фарнезоидного x-рецептора | |
| PH12015502031B1 (en) | Tetrahydropyrrolothiazine compounds | |
| EA201691216A1 (ru) | Композиции линаклотида с замедленным высвобождением | |
| EA201792021A1 (ru) | Ингибитор jak | |
| UY35683A (es) | Polimorfo de inhibidores de tirosina quinasa de bazo (syk) | |
| EA201690911A1 (ru) | Соединения диметилбензойной кислоты | |
| EP3504185A4 (en) | NEW SUBSTITUTED N'-HYDROXYCARBAMIMIDOYL-1,2,5-OXADIAZOLE COMPOUNDS AS INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | |
| MX2020003020A (es) | Compuestos de aminocarbonilcarbamato. | |
| CL2017000484A1 (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| BR112017019850A2 (pt) | ?processo melhorado para a preparação de apremilast? | |
| EA201691999A1 (ru) | Новые сульфониламинобензамидные соединения | |
| EA201791645A1 (ru) | Новые соли и полиморфы scy-078 | |
| EA201591717A1 (ru) | Твердые формы гидрохлорида вемурафениба | |
| BR112017013286A2 (pt) | composto de isoxazolina, e, uso de um composto de isoxazolina. | |
| EA201790191A1 (ru) | Новые сульфониламинобензамидные соединения | |
| BR112015024859A2 (pt) | processo e intermediários para a preparação de pregabalina | |
| BR112019002828A2 (pt) | método de preparação de derivados de estireno substituído | |
| BR112018069255A2 (pt) | processos para a preparação de ácidos heteroaril carboxílicos | |
| BR112016028698A2 (pt) | preparação de piperidina-4-carbotioamida | |
| BR112015028751A2 (pt) | processo para a preparação de derivados de 3,5-bis (fluoralquil)pirazol a partir de alfa,alfa-dihaloaminas | |
| CL2016002925A1 (es) | Procedimiento mejorado para preparar ácidos crotónicos sustituidos | |
| EA201791098A1 (ru) | Способ синтеза производных бензазепина | |
| MX2017004770A (es) | Formas solidas del clorhidrato de nilotinib. |